ConductScience.org, home
A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)
API referenceFor AI assistants

Trial · NCT02554812

Participant flow108

How many started, completed or left each group, period by period.

1 to 20 of 108

Download this page as JSON
PeriodMilestoneGroupParticipantsUnits counted
Overall StudySTARTEDCombination A Phase 1b NSCLC: Utomilumab 500 mg + Avelumab29
Overall StudySTARTEDCombination A Phase 1b NSCLC: Utomilumab 100 mg + Avelumab28
Overall StudySTARTEDCombination A Phase 1b NSCLC: Utomilumab 20 mg + Avelumab29
Overall StudySTARTEDCombination A Phase 2 Melanoma: Utomilumab 100 mg + Avelumab28
Overall StudySTARTEDCombination A Phase 2 SCCHN: Utomilumab 100 mg + Avelumab35
Overall StudySTARTEDCombination A Phase 2 TNBC: Utomilumab 100 mg + Avelumab21
Overall StudySTARTEDCombination A Phase 2 SCLC: Utomilumab 100 mg + Avelumab10
Overall StudySTARTEDCombination A Phase 2 First Line (1L) NSCLC: Utomilumab 100 mg + Avelumab21
Overall StudySTARTEDCombination A Phase 2 1L NSCLC: Utomilumab Then Utomilumab + Avelumab11
Overall StudySTARTEDCombination A Phase 2 1L NSCLC: Avelumab Then Utomilumab + Avelumab11
Overall StudySTARTEDCombination B Phase 1b: PF-04518600 0.3 mg/kg + Avelumab12
Overall StudySTARTEDCombination B Phase 1b: PF-04518600 1.0 mg/kg + Avelumab12
Overall StudySTARTEDCombination B Phase 1b: PF-04518600 3.0 mg/kg + Avelumab8
Overall StudySTARTEDCombination B Phase 2 NSCLC: PF-04518600 0.3 mg/kg + Avelumab14
Overall StudySTARTEDCombination B Phase 2 SCCHN: PF-04518600 0.3 mg/kg + Avelumab25
Overall StudySTARTEDCombination C Phase 1b: PD 0360324 50 mg + Avelumab10
Overall StudySTARTEDCombination C Phase 1b: PD 0360324 100 mg + Avelumab8
Overall StudySTARTEDCombination C Phase 1b: PD 0360324 150 mg + Avelumab6
Overall StudySTARTEDCombination D Phase 1b: Utomilumab 20 mg + PF-04518600 0.1 mg/kg + Avelumab12
Overall StudySTARTEDCombination D Phase 1b: Utomilumab 50 mg + PF-04518600 0.1 mg/kg + Avelumab12

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02554812/flow

API referenceFor AI assistants